

Muthiah Vaduganathan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7604998/muthiah-vaduganathan-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

291
papers

8,147
citations

40
h-index

82
g-index

345
ext. papers

11,713
ext. citations

8.1
avg. IF

6.86
L-index

#	Paper	IF	Citations
291	Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020 , 382, 1653-1659	59.2	1316
290	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1123-1133	15.1	1160
289	Rehospitalization for heart failure: problems and perspectives. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 391-403	15.1	434
288	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2365-2383	15.1	147
287	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020 , 141, 352-361	16.7	145
286	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 556-569	15.1	135
285	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. <i>Lancet, The</i> , 2020 , 396, 121-128	40	133
284	The vulnerable phase after hospitalization for heart failure. <i>Nature Reviews Cardiology</i> , 2015 , 12, 220-9	14.8	129
283	Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment. <i>JAMA Cardiology</i> , 2018 , 3, 642-649	16.2	111
282	Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 280-288	15.1	110
281	Clinical Outcomes in Young US Adults Hospitalized With COVID-19. <i>JAMA Internal Medicine</i> , 2020 ,	11.5	89
280	Thirty-day readmissions: the clock is ticking. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 345-6	27.4	87
279	The rise and fall of aspirin in the primary prevention of cardiovascular disease. <i>Lancet, The</i> , 2019 , 393, 2155-2167	40	85
278	Oral Anticoagulation in Patients With Liver Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2162-2175	15.1	83
277	Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 2524-2526	27.4	81
276	Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes. <i>JAMA Network Open</i> , 2020 , 3, e1918962	10.4	81
275	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1264-1272	15.1	79

274	Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1827-1845	15.1	79
273	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. <i>JAMA Cardiology</i> , 2018 , 3, 1011-1019	16.2	79
272	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , 2019 , 42, 2298-2306	14.6	70
271	The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1823-32	15.1	67
270	Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 513-7	15.1	66
269	Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 750-8	7.6	62
268	The disconnect between phase II and phase III trials of drugs for heart failure. <i>Nature Reviews Cardiology</i> , 2013 , 10, 85-97	14.8	61
267	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 3370-3372	15.1	61
266	Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1336-1349	15.1	56
265	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1661-71	15.1	52
264	Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. <i>JACC: Heart Failure</i> , 2019 , 7, 1-12	7.9	51
263	Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018 , 6, 975-982	7.9	50
262	The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. <i>JACC: Heart Failure</i> , 2013 , 1, 488-96	7.9	49
261	Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 858-869	5.8	48
260	Marijuana Use in Patients With Cardiovascular Disease: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 320-332	15.1	47
259	Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 571-9	15.1	47
258	The Drug-Intoxication Epidemic and Solid-Organ Transplantation. <i>New England Journal of Medicine</i> , 2018 , 378, 1943-1945	59.2	47
257	Misclassification of Myocardial Injury as Myocardial Infarction: Implications for Assessing Outcomes in Value-Based Programs. <i>JAMA Cardiology</i> , 2019 , 4, 460-464	16.2	45

256	Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. <i>JACC: Heart Failure</i> , 2021 , 9, 65-73	7.9	44
255	Type 2 Myocardial Infarction-Diagnosis, Prognosis, and Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 433-434	27.4	41
254	Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 245-254	15.1	41
253	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 862-874	7.9	40
252	The immunological axis in heart failure: importance of the leukocyte differential. <i>Heart Failure Reviews</i> , 2013 , 18, 835-45	5	40
251	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , 2014 , 19, 135-52	5	39
250	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. <i>European Heart Journal</i> , 2019 , 40, 3593-3602	9.5	38
249	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 176-185	15.1	36
248	Relation of body mass index to late survival after valvular heart surgery. <i>American Journal of Cardiology</i> , 2012 , 110, 1667-78	3	36
247	Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists. <i>JACC: Heart Failure</i> , 2019 , 7, 169-172	7.9	35
246	Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). <i>American Journal of Cardiology</i> , 2014 , 114, 1713-21	3	35
245	Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 653-661	7.9	34
244	Prognostic scores in heart failure - Critical appraisal and practical use. <i>International Journal of Cardiology</i> , 2015 , 188, 1-9	3.2	33
243	Hemoconcentration-guided diuresis in heart failure. <i>American Journal of Medicine</i> , 2014 , 127, 1154-9	2.4	32
242	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. <i>JAMA Cardiology</i> , 2017 , 2, 127-135	16.2	30
241	Association of the New Peer Group-Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. <i>JAMA Network Open</i> , 2019 , 2, e192987	10.4	29
240	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review. <i>JAMA Cardiology</i> , 2020 , 5, 714-722	16.2	29
239	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. <i>Circulation</i> , 2019 , 140, 1369-1379	16.7	28

238	Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies. <i>Circulation: Heart Failure</i> , 2015 , 8, 826-31	7.6	28
237	Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold. <i>American Journal of Cardiology</i> , 2016 , 117, 1231-5	3	28
236	Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). <i>American Journal of Cardiology</i> , 2015 , 115, 790-6 ³	6.3	28
235	Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2020 , 22, 472-485	12.3	28
234	Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials. <i>American Journal of Medicine</i> , 2018 , 131, 575-577	2.4	28
233	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. <i>JAMA Cardiology</i> , 2020 , 5, 1182-1190	16.2	27
232	Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. <i>JACC: Heart Failure</i> , 2020 , 8, 347-358	7.9	27
231	Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 401-8	7.6	27
230	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	26
229	Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. <i>Journal of Cardiovascular Medicine</i> , 2012 , 13, 415-22	1.9	26
228	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2020 , 7, 3298-3309	3.7	26
227	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 372-381	7.9	25
226	Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. <i>American Heart Journal</i> , 2014 , 168, 142-9	4.9	25
225	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 1000-1005	16.2	24
224	Sacubitril/Valsartan: Nephilysin Inhibition 5 Years After PARADIGM-HF. <i>JACC: Heart Failure</i> , 2020 , 8, 800-810	8.1	24
223	Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. <i>American Journal of Medicine</i> , 2016 , 129, 1002-5	2.4	24
222	Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. <i>European Journal of Heart Failure</i> , 2017 , 19, 682-685	12.3	23
221	Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1596-1598	15.1	23

220	Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. <i>JACC: Heart Failure</i> , 2020 , 8, 640-653	7.9	23
219	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1644-1656	15.1	23
218	Baseline Blood Pressure, the 2017 ACC/AHA High Blood Pressure Guidelines, and Long-Term Cardiovascular Risk in SPRINT. <i>American Journal of Medicine</i> , 2018 , 131, 956-960	2.4	23
217	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. <i>Circulation</i> , 2019 , 140, 2076-2088	16.7	23
216	Anticoagulation in heart failure: current status and future direction. <i>Heart Failure Reviews</i> , 2013 , 18, 797-813	5.13	22
215	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. <i>European Heart Journal</i> , 2020 , 41, 2356-2362	9.5	21
214	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. <i>Heart Failure Reviews</i> , 2016 , 21, 455-62	5	21
213	Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. <i>PLoS Medicine</i> , 2019 , 16, e1002797	11.6	20
212	Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. <i>American Journal of Cardiology</i> , 2019 , 124 Suppl 1, S20-S27	3	20
211	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from COVID-19: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	20
210	Fifteen-Year Trends in Management and Outcomes of Non-ST-Segment-Elevation Myocardial Infarction Among Black and White Patients: The ARIC Community Surveillance Study, 2000-2014. <i>Journal of the American Heart Association</i> , 2018 , 7, e010203	6	20
209	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 552-562	12.3	19
208	Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y inhibition from the IABP-SHOCK II trial. <i>Resuscitation</i> , 2019 , 137, 205-212	4	19
207	Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. <i>Circulation</i> , 2020 , 142, 230-243	16.7	19
206	Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 398-405	6.9	18
205	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 564-569	7.9	18
204	Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. <i>Cardiac Failure Review</i> , 2017 , 3, 122-129	4.2	18
203	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. <i>JACC: Heart Failure</i> , 2020 , 8, 844-855	7.9	18

202	Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2454-2464	15.1	17
201	Relation between ticagrelor response and levels of circulating reticulated platelets in patients with non-ST elevation acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 211-7	5.1	17
200	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016 , 117, 1144-50	3	16
199	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. <i>JACC: Heart Failure</i> , 2020 , 8, 469-480	7.9	16
198	Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2368-2378	15.1	16
197	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. <i>Circulation</i> , 2020 , 142, 1205-1218	16.7	16
196	Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 463-464	15.1	15
195	Effect of intensive glycaemic control on endothelial progenitor cells in patients with long-standing uncontrolled type 2 diabetes. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 1153-62	3.9	15
194	Prevalence of Apparent Treatment-Resistant Hypertension in the United States According to the 2017 High Blood Pressure Guideline. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 776-782	6.4	14
193	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. <i>Diabetes Care</i> , 2020 , 43, 1920-1928	14.6	14
192	Temporal Trends in Racial Differences in 30-Day Readmission and Mortality Rates After Acute Myocardial Infarction Among Medicare Beneficiaries. <i>JAMA Cardiology</i> , 2020 , 5, 136-145	16.2	14
191	Temporal Trends in Heart Failure Incidence Among Medicare Beneficiaries Across Risk Factor Strata, 2011 to 2016. <i>JAMA Network Open</i> , 2020 , 3, e2022190	10.4	14
190	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. <i>JAMA Internal Medicine</i> , 2020 , 180, 141-144	11.5	14
189	Patient Characteristics and Clinical Outcomes of Type 1 Versus Type 2 Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 848-857	15.1	14
188	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 330-343	15.1	14
187	Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. <i>Circulation: Heart Failure</i> , 2020 , 13, e006623	7.6	13
186	Trends in Heart Failure Clinical Trials From 2001-2012. <i>Journal of Cardiac Failure</i> , 2016 , 22, 171-9	3.3	13
185	Implications of Specialist Density for Diabetes Care in the United States. <i>JAMA Cardiology</i> , 2019 , 4, 1174-1175	16.75	13

184	Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1648-1659	3.9	13
183	A triad of linezolid toxicity: hypoglycemia, lactic acidosis, and acute pancreatitis. <i>Baylor University Medical Center Proceedings</i> , 2015 , 28, 466-8	0.6	13
182	Angioedema in COVID-19. <i>European Heart Journal</i> , 2020 , 41, 3283-3284	9.5	13
181	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). <i>European Journal of Heart Failure</i> , 2021 , 23, 1499-1511 ¹³	12.3	13
180	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. <i>Circulation</i> , 2019 , 140, 2108-2118	16.7	13
179	High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. <i>Journal of the American Heart Association</i> , 2018 , 7, e010364	6	13
178	Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016 , 117, 340-6	3	12
177	Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	12
176	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e012797	6	12
175	Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes. <i>JACC: Heart Failure</i> , 2021 , 9, 215-223	7.9	12
174	Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial. <i>American Journal of Medicine</i> , 2019 , 132, 840-846	2.4	11
173	Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). <i>JAMA Cardiology</i> , 2020 , 5, 576-581	16.2	11
172	Type 2 Myocardial Infarction and the Hospital Readmission Reduction Program. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1166-1170	15.1	11
171	Application of the H FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1288-1291	12.3	11
170	Epidemiology of hospitalized heart failure: differences and similarities between patients with reduced versus preserved ejection fraction. <i>Heart Failure Clinics</i> , 2013 , 9, 271-6, v	3.3	11
169	Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study. <i>European Journal of Heart Failure</i> , 2021 , 23, 1191-1201	12.3	11
168	Thirty-Day Readmissions After Hospitalization for Hypertensive Emergency. <i>Hypertension</i> , 2019 , 73, 60-67.5	6.5	11
167	Pulse Pressure, Cardiovascular Events, and Intensive Blood-Pressure Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>American Journal of Medicine</i> , 2019 , 132, 733-739	2.4	11

166	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019 , 12, e006125	7.6	10
165	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 799-809	2.5	10
164	Death due to munchausen syndrome: a case of idiopathic recurrent right ventricular failure and a review of the literature. <i>Psychosomatics</i> , 2014 , 55, 668-72	2.6	10
163	Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure. <i>JAMA Cardiology</i> , 2020 , 5, 336-339	16.2	10
162	Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 356-363	6.4	10
161	Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy. <i>European Journal of Heart Failure</i> , 2021 , 23, 384-392	12.3	10
160	Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. <i>JACC: Heart Failure</i> , 2021 , 9, 1-12	7.9	10
159	Organ Donation and Drug Intoxication-Related Deaths in the United States. <i>New England Journal of Medicine</i> , 2019 , 380, 597-599	59.2	9
158	Angiotensin-Nepriylsin Inhibition as a Paradigm for All?. <i>Current Cardiology Reports</i> , 2016 , 18, 115	4.2	9
157	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9,	6	9
156	Midterm benefits of preoperative statin therapy in patients undergoing isolated valve surgery. <i>Annals of Thoracic Surgery</i> , 2012 , 93, 1881-7	2.7	9
155	Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017 , 120, 359-361	3	9
154	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). <i>American Journal of Cardiology</i> , 2017 , 120, 1043-1048	3	9
153	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1635-1654	15.1	9
152	Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk. <i>European Journal of Heart Failure</i> , 2021 , 23, 1002-1008	12.3	9
151	Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. <i>American Journal of Cardiology</i> , 2016 , 117, 1845-50	3	8
150	Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014 , 114, 743-50	3	8
149	Drug therapy to reduce early readmission risk in heart failure: ready for prime time?. <i>JACC: Heart Failure</i> , 2013 , 1, 361-364	7.9	8

148	Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	8
147	Emerging Trends in Financing of Adult Heart Transplantation in the United States. <i>JACC: Heart Failure</i> , 2019 , 7, 56-62	7.9	8
146	Trends in Female Authorship: A Bibliometric Analysis of The Annals of Thoracic Surgery. <i>Annals of Thoracic Surgery</i> , 2021 , 111, 1387-1393	2.7	8
145	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. <i>JAMA Cardiology</i> , 2020 ,	16.2	8
144	Physician Density by Specialty Type in Urban and Rural Counties in the US, 2010 to 2017. <i>JAMA Network Open</i> , 2021 , 4, e2033994	10.4	8
143	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. <i>Circulation</i> , 2018 , 137, 938-947	16.7	8
142	Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. <i>JAMA Cardiology</i> , 2020 , 5, 515-521	16.2	7
141	Running thin: implications of a heparin shortage. <i>Lancet, The</i> , 2020 , 395, 534-536	4.0	7
140	Cardio-Renal-Metabolic Care Models: Toward Achieving Effective Interdisciplinary Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e007264	5.8	7
139	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 2004-2012	15.1	7
138	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1961-1973	15.1	7
137	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1518-1524	12.3	7
136	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 382-391	3	7
135	Prevalence and Prognostic Significance of Mitral Regurgitation in Acute Decompensated Heart Failure: The ARIC Study. <i>JACC: Heart Failure</i> , 2021 , 9, 179-189	7.9	7
134	Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018. <i>American Heart Journal</i> , 2022 , 243, 103-109	4.9	7
133	Prognostic implications of fasting plasma glucose in subjects with echocardiographic abnormalities. <i>International Journal of Cardiology</i> , 2017 , 241, 423-429	3.2	6
132	Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 1647-1658	2.3	6
131	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. <i>Circulation: Heart Failure</i> , 2020 , 13, e006758	7.6	6

130	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. <i>JACC: Heart Failure</i> , 2020 , 8, 618-626	7.9	6
129	Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2013 , 112, 1763-9	3	6
128	Large-volume barium aspiration. <i>Baylor University Medical Center Proceedings</i> , 2015 , 28, 183-4	0.6	6
127	Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database. <i>JAMA Cardiology</i> , 2021 , 6, 92-96	16.2	6
126	Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 374-382	7.9	6
125	Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials. <i>Stroke</i> , 2021 , 52, e217-e223	6.7	6
124	Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients. <i>Journal of General Internal Medicine</i> , 2021 , 36, 2532-2535	4	6
123	Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. <i>European Journal of Heart Failure</i> , 2021 , 23, 1468-1476	12.3	6
122	Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?. <i>European Journal of Heart Failure</i> , 2016 , 18, 128-32	12.3	6
121	The First 4 Years of Postmarketing Safety Surveillance Related to the MitraClip Device: A United States Food and Drug Administration MAUDE Experience. <i>Journal of Invasive Cardiology</i> , 2020 , 32, E130-E132	0.7	6
120	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , 2017 , 230, 301-303	3.2	5
119	Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2517-2521	15.1	5
118	Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries. <i>JAMA Network Open</i> , 2020 , 3, e200181	10.4	5
117	Thirty-Day Nonindex Readmissions and Clinical Outcomes After Cardiac Surgery. <i>Annals of Thoracic Surgery</i> , 2020 , 110, 484-491	2.7	5
116	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. <i>Current Heart Failure Reports</i> , 2018 , 15, 10-16	2.8	5
115	Expanding the scope of the "polypill" to heart failure. <i>Journal of Cardiac Failure</i> , 2013 , 19, 540-1	3.3	5
114	Modern drug development: which patients should come first?. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 2619-20	27.4	5
113	Gender differences in industry payments among cardiologists. <i>American Heart Journal</i> , 2020 , 223, 123-131	19	5

112	Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. <i>Diabetologia</i> , 2021 , 64, 1583-1594	10.3	5
111	Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19. <i>Circulation</i> , 2021 , 144, 177-187		5
110	Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. <i>Current Diabetes Reports</i> , 2019 , 19, 157	5.6	5
109	Association of Medicaid Expansion With Rates of Utilization of Cardiovascular Therapies Among Medicaid Beneficiaries Between 2011 and 2018. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e007492	5.8	5
108	Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum: Insights From the UK Biobank. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 453-464	15.1	5
107	Wake Forest University long-term follow-up of type 2 myocardial infarction: The Wake-Up T2MI Registry. <i>Clinical Cardiology</i> , 2019 , 42, 592-604	3.3	4
106	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 1660-1666	3	4
105	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2018 , 122, 255-260	3	4
104	Lipids, statins, and clinical outcomes in heart failure: rethinking the data. <i>Heart Failure Reviews</i> , 2014 , 19, 695-8	5	4
103	Cardiologist Evaluation of Patients With Type 2 Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e007440	5.8	4
102	Developing evidence-based and accountable health policy in heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 1653-1656	12.3	4
101	The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials: A Report of 348 Studies Registered With ClinicalTrials.gov. <i>JACC: Clinical Electrophysiology</i> , 2018 , 4, 944-954	4.6	4
100	Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. <i>JAMA Cardiology</i> , 2021 ,	16.2	4
99	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 184-197	7.9	4
98	IMAGES IN CLINICAL MEDICINE. Ping-Pong Gaze. <i>New England Journal of Medicine</i> , 2015 , 372, e34	59.2	3
97	Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. <i>Heart Failure Reviews</i> , 2015 , 20, 393-400	5	3
96	Roadmap to inpatient heart failure management. <i>Journal of Cardiology</i> , 2015 , 65, 26-31	3	3
95	Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. <i>Circulation: Heart Failure</i> , 2020 , 13, e006638	7.6	3

94	Expanding the global borders of heart failure: the SHOP and PEOPLE studies. <i>European Heart Journal</i> , 2018 , 39, 1781-1783	9.5	3
93	Metastatic pancreatic neuroendocrine tumor with ectopic adrenocorticotrophic hormone production. <i>Baylor University Medical Center Proceedings</i> , 2015 , 28, 46-9	0.6	3
92	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1587-1598	15.1	3
91	What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?. <i>Current Diabetes Reports</i> , 2020 , 20, 63	5.6	3
90	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. <i>Diabetes Care</i> , 2020 , 43, 2684-2690	14.6	3
89	Longitudinal trajectories of hospital performance across targeted cardiovascular conditions in the USA. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 62-71	4.6	3
88	Temporal trends in risk profiles among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2021 , 232, 154-163	4.9	3
87	Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. <i>JAMA Cardiology</i> , 2021 , 6, 354-357	16.2	3
86	Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. <i>International Journal of Cardiology</i> , 2021 , 323, 188-191	3.2	3
85	Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations. <i>Heart Failure Clinics</i> , 2015 , 11, 591-601	3.3	2
84	Assessment of Heterogeneity in Heart Failure-Related Meta-Analyses. <i>Circulation: Heart Failure</i> , 2020 , 13, e007070	7.6	2
83	Orphan Drug Development in Cardiovascular Medicine. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006509	5.8	2
82	Design and rationale of the North Indian ST-Segment Elevation Myocardial Infarction Registry: A prospective cohort study. <i>Clinical Cardiology</i> , 2019 , 42, 1140-1146	3.3	2
81	Classification of patients hospitalized for heart failure. <i>Heart Failure Clinics</i> , 2013 , 9, 277-83, v	3.3	2
80	Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012). <i>American Journal of Cardiology</i> , 2015 , 116, 307-12	3	2
79	Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy?. <i>American Journal of Medicine</i> , 2014 , 127, 574-8	2.4	2
78	Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018.. <i>ESC Heart Failure</i> , 2022 ,	3.7	2
77	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. <i>Journal of Diabetes and Its Complications</i> , 2021 , 36, 108101	3.2	2

76	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 432-444	15.1	2
75	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	2
74	Angiotensin receptor-neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 1525-1530	12.3	2
73	Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. <i>Current Opinion in Cardiology</i> , 2020 , 35, 517-523	2.1	2
72	Extensive Arterial Thrombosis in Covid-19. <i>American Journal of Cardiology</i> , 2020 , 134, 148-149	3	2
71	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. <i>Circulation</i> , 2021 , 143, 949-958	16.7	2
70	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. <i>European Journal of Heart Failure</i> , 2021 , 23, 1346-1356	12.3	2
69	Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1280-1284	3.3	2
68	Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 2608-2616	3.7	2
67	Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. <i>International Journal of Cardiology</i> , 2016 , 214, 16-8	3.2	2
66	One-Year Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Varying Quantities of Coronary Artery Calcium (from a 13-Year Registry). <i>American Journal of Cardiology</i> , 2016 , 118, 1111-1116	3	2
65	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019 , 7, 1022-1028	7.9	2
64	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. <i>ESC Heart Failure</i> , 2021 , 8, 26-36	3.7	2
63	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Geriatrics Society</i> , 2021 , 69, 1309-1318	5.6	2
62	Trends, Management, and Outcomes of Acute Myocardial Infarction Hospitalizations With In-Hospital-Onset Versus Out-of-Hospital Onset: The ARIC Study. <i>Journal of the American Heart Association</i> , 2021 , 10, e018414	6	2
61	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021 , 237, 45-53	4.9	2
60	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2775-2784	6.7	2
59	The Intersection of Type 2 Myocardial Infarction and Heart Failure. <i>Journal of the American Heart Association</i> , 2021 , 10, e020849	6	2

58	Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. <i>Progress in Cardiovascular Diseases</i> , 2021 , 68, 97-98	8.5	2
57	Reply: Are We Missing Something in the Management of Acute Coronary Syndromes in COVID-19-Negative Patients?. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2574-2575	15.1	1
56	Response to Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> 2019;42:2298-2306. <i>Diabetes Care</i> , 2020 , 43, e26-e27	14.6	1
55	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. <i>American Journal of Cardiology</i> , 2020 , 125, 1577 ² 1581 ¹		
54	Pectus Excavatum and Right Ventricular Compression in a Young Athlete with Syncope. <i>American Journal of Medicine</i> , 2018 , 131, e451-e453	2.4	1
53	Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials. <i>Current Heart Failure Reports</i> , 2017 , 14, 203-209	2.8	1
52	Dual antiplatelet therapy after stent implantation. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1446	27.4	1
51	In reply to Loh and Lin. <i>Academic Medicine</i> , 2014 , 89, 530	3.9	1
50	Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure.. <i>ESC Heart Failure</i> , 2022 ,	3.7	1
49	Serum Potassium and Mortality in High-Risk Patients: SPRINT. <i>Hypertension</i> , 2021 , 78, 1586-1594	8.5	1
48	Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121008403	7.6	1
47	Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 177-179 ^{4.6}	4.6	1
46	Transforming the interpretation of significance in heart failure trials. <i>European Journal of Heart Failure</i> , 2020 , 22, 177-180	12.3	1
45	Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019. <i>Heart Failure Clinics</i> , 2020 , 16, 433-440	3.3	1
44	Intensive vs. standard blood pressure control and vascular procedures: insights from the Systolic Blood Pressure Intervention Trial (SPRINT). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e35-e37	6.4	1
43	Effect of government-issued state of emergency and reopening orders on cardiovascular hospitalizations during the COVID-19 pandemic. <i>American Journal of Preventive Cardiology</i> , 2021 , 6, 1001 ^{1.9} 1001 ¹ 72	1.9	1
42	Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. <i>Heart</i> , 2021 , 107, 1407-1416	5.1	1
41	Coronary stenting approaches in the treatment of chronic total occlusion: contemporary registry-based experience. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17, 673-9	1.9	1

40	Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches. <i>Heart Failure Reviews</i> , 2021 , 26, 11-21	5	1
39	Intensive blood pressure control appears to be effective and safe in patients with peripheral artery disease: the Systolic Blood Pressure Intervention Trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e38-e40	6.4	1
38	Moving Beyond the Hospital. <i>Circulation</i> , 2018 , 138, 2169-2171	16.7	1
37	Optimizing the Detection of Left Ventricular Thrombus Following Acute Myocardial Infarction in the Current Era-Reply. <i>JAMA Cardiology</i> , 2018 , 3, 1129	16.2	1
36	Gender Differences in Medicare Payments Among Cardiologists. <i>JAMA Cardiology</i> , 2021 ,	16.2	1
35	Hospitalizations and Outcomes of T1MI Observed Before and After the Introduction of MI Subtype Codes. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1242-1253	15.1	1
34	Contemporary Nationwide Heart Transplantation and Left Ventricular Assist Device Outcomes in Patients with Histories of Bariatric Surgery. <i>Journal of Cardiac Failure</i> , 2021 ,	3.3	1
33	Contemporary Burden of Primary Versus Secondary Heart Failure Hospitalizations in the United States. <i>American Journal of Cardiology</i> , 2021 , 156, 140-142	3	1
32	Patterns of Use and Clinical Outcomes with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure and Changes in Kidney Function: An Analysis of the Veterans Health Administrative Database. <i>CardioRenal Medicine</i> , 2021 , 1-11	2.8	1
31	Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121009099	7.6	1
30	Trends in Anticoagulation Prescription Spending Among Medicare Part D and Medicaid Beneficiaries Between 2014 and 2019. <i>Journal of the American Heart Association</i> , 2021 , e022644	6	1
29	Reply: Intersection of fasting plasma glucose, adverse cardiac remodeling, and clinical outcomes. <i>International Journal of Cardiology</i> , 2018 , 252, 214-215	3.2	0
28	Torus palatinus. <i>Baylor University Medical Center Proceedings</i> , 2014 , 27, 259	0.6	0
27	Physician Practice Pattern Variations in Common Clinical Scenarios Within 5 US Metropolitan Areas. <i>JAMA Health Forum</i> , 2022 , 3, e214698	2	0
26	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 504-510	15.1	0
25	Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121008597	7.6	0
24	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents.. <i>JACC: Heart Failure</i> , 2022 , 10, 1-11	7.9	0
23	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e021494	6.4	0

22	Prognosis for patients with heart failure and reduced ejection fraction with and without diabetes: A 7-year nationwide veteran administration analysis. <i>International Journal of Cardiology</i> , 2022 , 346, 30-34	3.2	o
21	Amyloidosis and 30-Day Outcomes Among Patients With Heart Failure: A Nationwide Readmissions Database Study. <i>JACC: CardioOncology</i> , 2020 , 2, 710-718	3.8	o
20	Citizenship Status and Cardiothoracic Organ Transplantation in the United States. <i>Circulation: Heart Failure</i> , 2020 , 13, e007788	7.6	o
19	Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). <i>American Journal of Cardiology</i> , 2021 , 158, 59-65	3	o
18	Marijuana Use and In-Hospital Outcomes After Percutaneous Coronary Intervention in Michigan, United States. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1757-1767	5	o
17	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2021 , 21, 41	5.6	o
16	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2018 , 16, 123-131	2.5	
15	The Reply. <i>American Journal of Medicine</i> , 2018 , 131, e267-e268	2.4	
14	Does dual vs. triple antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation lower the risk of bleeding at the cost of increased risk of ischemic events?. <i>IJC Heart and Vasculature</i> , 2019 , 24, 100404	2.4	
13	Aspirin Resistance 2014 , 277-284		
12	Sudden flare of rheumatoid arthritis associated with newly diagnosed atrial flutter. <i>Baylor University Medical Center Proceedings</i> , 2014 , 27, 233-4	0.6	
11	Acute lymphocytic leukemia with superimposed invasive aspergillosis and pneumopericardium successfully treated with voriconazole. <i>Baylor University Medical Center Proceedings</i> , 2014 , 27, 250-2	0.6	
10	Influence of chronic kidney disease on warfarin therapy for atrial fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 2541-2	27.4	
9	Association of Readmission Penalty Amount with Subsequent 30-Day Risk Standardized Readmission and Mortality Rates Among Patients Hospitalized with Heart Failure: An Analysis of Get With The Guidelines - Heart Failure Participating Centers.. <i>American Heart Journal</i> , 2021 , 246, 1-1	4.9	
8	Quantifying the Impact of Care Fragmentation on Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2020 , 128, 113-119	3	
7	Considering dose in pharmacological therapies for heart failure - AuthorsReply. <i>Lancet, The</i> , 2021 , 397, 275	4 ^o	
6	The Reply. <i>American Journal of Medicine</i> , 2018 , 131, e389-e390	2.4	
5	The Reply. <i>American Journal of Medicine</i> , 2018 , 131, e263	2.4	

4	Hospitalization of Patients With (But Not for) Heart Failure: An Opportunity for Accelerated Guideline-Directed Medical Therapy Optimization?. <i>Journal of Cardiac Failure</i> , 2021 , 27, 910-912	3.3
3	Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1027-1030	3.3
2	Modifiable Risk Factor Burden Among 3 Different Age Groups with Heart Failure. <i>American Journal of Cardiology</i> , 2021 , 156, 150-152	3
1	Implementation of Cardiometabolic Centers and Training Programs.. <i>Current Diabetes Reports</i> , 2022 , 1	5.6